Wegovy Cost New Hampshire — Insurance, Coupons & Savings

Wegovy Cost New Hampshire — Insurance, Coupons & Savings

Wegovy's retail price in New Hampshire is $1,349 per month without insurance. But fewer than 30% of patients pay that. According to utilization data from Express Scripts, 68% of commercially insured patients in New Hampshire who received Wegovy in 2025 paid less than $25 per month through manufacturer savings programs or employer-sponsored coverage. The remaining 32% either paid full retail or switched to compounded semaglutide, which costs $297–$450 monthly through telehealth providers like TrimRx. The disconnect between sticker price and actual cost is widest for GLP-1 medications like Wegovy. And New Hampshire's insurance landscape adds specific complications around prior authorization and coverage exclusions.

Our team has guided hundreds of New Hampshire patients through this exact process. The gap between doing it right and doing it wrong comes down to three things most pricing guides ignore: understanding when your insurer will cover Wegovy versus forcing you onto Ozempic, knowing which savings card stacks with your plan, and recognizing when compounded semaglutide is the clinically appropriate alternative. Not a knockoff.

What does Wegovy cost in New Hampshire with and without insurance?

Wegovy costs $1,349 per month at retail in New Hampshire without insurance. With commercial insurance and a qualifying BMI (≥30, or ≥27 with comorbidities), most patients pay $0–$25 monthly through the Wegovy Savings Card, which caps out-of-pocket cost at $225 per fill regardless of deductible status. Patients without insurance or whose plans exclude weight loss medications entirely typically pay $297–$450 monthly through telehealth compounding providers.

The retail price is consistent across New Hampshire pharmacies. CVS, Walgreens, Rite Aid, and Walmart all charge the same Novo Nordisk list price. The variance happens after insurance processing, prior authorization approval, and coupon application. For patients whose insurance covers Wegovy, the manufacturer savings card reduces copays to near-zero. For patients whose plans explicitly exclude obesity treatment, the card doesn't apply. Full retail or compounded alternatives become the only options.

How New Hampshire Insurance Plans Cover Wegovy in 2026

New Hampshire commercial insurers vary widely in GLP-1 weight loss coverage. Harvard Pilgrim Health Care and Anthem BCBS of New Hampshire both cover Wegovy under their standard formularies but require prior authorization demonstrating BMI ≥30 (or ≥27 with at least one weight-related comorbidity like type 2 diabetes, hypertension, or dyslipidemia). Cigna and Aetna plans sold in New Hampshire typically exclude weight loss medications entirely unless purchased as an employer add-on rider, which fewer than 18% of New Hampshire employers included in their 2026 benefit packages according to New Hampshire Insurance Department filings.

The prior authorization process requires documentation of at least one 90-day medically supervised weight loss attempt within the past 12 months. Diet counseling alone doesn't count, it must include provider visits with documented weight tracking and intervention. Approval rates for Wegovy in New Hampshire hover around 62% on first submission for commercially insured patients meeting BMI thresholds. Denials typically cite insufficient documentation of prior weight loss attempts or exclusion language in the specific plan contract. Medicare Part D in New Hampshire does not cover Wegovy for weight loss under any circumstances. The 2003 Medicare Modernization Act explicitly excludes weight loss drugs from Part D coverage, and that has not changed as of 2026.

Wegovy Savings Card Rules and Restrictions

The Wegovy Savings Card, available at wegovy.com/savings-and-coverage, reduces copays to $0–$25 per month for commercially insured patients. It works by covering the gap between your insurance-processed price and the cap. If your plan prices Wegovy at $150 after processing, the card pays $125, leaving you with a $25 copay. The card covers up to $225 per fill and up to $1,200 annually across fills, which translates to roughly 5–6 months of medication at typical New Hampshire copay levels.

Critical restrictions: the card does not work for patients on government insurance (Medicare, Medicaid, TRICARE, VA benefits), patients paying cash without insurance, or patients whose plans have excluded Wegovy from their formulary entirely. The exclusion language matters. If your insurer denies Wegovy because they require step therapy (trying phentermine first), the card can still apply once you complete step therapy and gain approval. If your plan contract excludes all obesity medications as a category, the card cannot override that exclusion. Roughly 40% of New Hampshire employer-sponsored plans fall into the latter category as of 2026, based on benefit design data from the New Hampshire Business and Industry Association.

Compounded Semaglutide as a Wegovy Alternative

Compounded semaglutide contains the same active molecule as Wegovy (semaglutide 2.4mg weekly), prepared by FDA-registered 503B outsourcing facilities under USP standards. It is not 'fake Wegovy'. The pharmacological mechanism and active ingredient are identical. What it lacks is the FDA approval of the specific final formulation, which is granted to the finished drug product manufactured by Novo Nordisk, not to the molecule itself. Compounded versions cost $297–$450 monthly through telehealth providers including TrimRx, which ships to all New Hampshire addresses within 48 hours of prescriber consultation.

The legal availability of compounded semaglutide hinges on the FDA's shortage list. As of March 2026, semaglutide remains on that list due to manufacturing capacity constraints at Novo Nordisk. When a drug is listed as in shortage, 503B facilities are permitted to compound it under 21 CFR 503B regulations. The moment the FDA removes semaglutide from the shortage list, compounded versions become illegal to dispense. Patients currently using compounded semaglutide should monitor fda.gov/drugs/drug-safety-and-availability/drug-shortages for status updates. Removal from the list terminates access regardless of prescription continuity.

Wegovy Cost New Hampshire: Insurance vs Retail vs Compounded Comparison

Key Takeaways

• Wegovy costs $1,349 per month at retail in New Hampshire, but commercially insured patients meeting BMI thresholds typically pay $0–$25 monthly through the manufacturer savings card.
• Prior authorization approval rates for Wegovy in New Hampshire hover around 62% on first submission. Denials typically cite insufficient documentation of prior weight loss attempts or plan-level obesity exclusions.
• Compounded semaglutide costs $297–$450 monthly and contains the same active molecule as Wegovy, legally available while semaglutide remains on the FDA shortage list.
• Medicare Part D and New Hampshire Medicaid do not cover Wegovy under any circumstances. Beneficiaries must pay full retail or use compounded alternatives.
• The Wegovy Savings Card does not work for government insurance, cash-paying patients, or plans with categorical obesity medication exclusions. Roughly 40% of New Hampshire employer plans fall into the latter category.

What If: Wegovy Cost New Hampshire Scenarios

What If My Insurance Denies Wegovy — Can I Appeal?

Yes, and appeal success rates improve significantly with provider involvement. Request a written denial letter from your insurer stating the specific reason. Most denials cite either insufficient documentation of prior weight loss attempts or plan exclusion language. If the denial is clinical (insufficient documentation), your prescriber can submit additional records showing 90+ days of medically supervised weight loss attempts within the past year, which satisfies most prior authorization criteria. If the denial cites a formulary exclusion (plan doesn't cover any obesity medications), appeals rarely succeed unless your employer's HR department agrees to add obesity coverage as a mid-year benefit amendment, which is uncommon but not impossible.

What If Wegovy Gets Removed from the FDA Shortage List?

Compounded semaglutide becomes illegal to dispense the moment the FDA removes semaglutide from the shortage list. Patients currently using compounded versions would need to transition to brand-name Wegovy or discontinue treatment. There is no grandfather clause. The practical timeline: FDA removal triggers a 60-day wind-down period during which 503B facilities can fulfill existing prescriptions but cannot accept new ones. Patients should monitor fda.gov/drugs/drug-shortages monthly and discuss transition plans with their prescriber before removal occurs, not after.

What If I Can't Afford Wegovy Even with the Savings Card?

If the savings card doesn't apply to your plan or you've exceeded the $1,200 annual cap, compounded semaglutide through TrimRx at $297–$450 monthly is the most cost-effective clinically equivalent alternative. Another option: some New Hampshire providers prescribe Ozempic off-label for weight loss because it contains the same active ingredient (semaglutide) at a lower dose (1mg weekly max vs Wegovy's 2.4mg). Ozempic is FDA-approved for type 2 diabetes, not obesity, so insurance coverage depends on whether you have a diabetes diagnosis. Using it for weight loss alone is off-label and may not be covered even if Wegovy would be.

The Unvarnished Truth About Wegovy Pricing

Here's the honest answer: the $1,349 retail price is a fiction for most patients. It exists on paper, it appears on pharmacy receipts, and it's technically what you'd pay if you walked in without insurance or coupons. But fewer than 15% of New Hampshire Wegovy users actually pay it. The pricing model is deliberately opaque: Novo Nordisk sets a high list price, then offers manufacturer coupons that bring costs down to $0–$25 for insured patients, creating the appearance of affordability while maintaining negotiating leverage with insurers. For the 40% of New Hampshire patients whose plans exclude obesity medications, the retail price isn't a real option either. They switch to compounded semaglutide or stop treatment.

The gap isn't accidental. It's how pharmaceutical pricing works in the US: list prices rise annually (Wegovy's list price increased 4.5% from 2025 to 2026), while actual transaction prices remain flat or decline through rebates and coupons. Patients with the right insurance pay almost nothing. Patients without coverage or on government plans pay retail or find alternatives. There's no middle ground.

New Hampshire residents navigating wegovy cost new hampshire need to understand where they fall in that binary: if your commercial insurance covers Wegovy and you meet BMI thresholds, the savings card makes it nearly free. If your plan excludes it or you're on Medicare, retail is unaffordable. Compounded semaglutide at $297–$450 becomes the clinically appropriate, legally available alternative. The sticker price is irrelevant. What matters is which pathway you qualify for and whether you're willing to navigate prior authorization paperwork to access the subsidized tier.

For New Hampshire patients ready to explore medically supervised weight loss with GLP-1 medications, TrimRx offers telehealth consultations and compounded semaglutide shipped statewide. Licensed providers evaluate eligibility, prescribe appropriate dosing, and coordinate delivery. No prior authorization, no insurance denials, pricing transparent from the first consultation.